Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) reached a new 52-week high on Friday . The stock traded as high as $24.95 and last traded at $22.87, with a volume of 215700 shares changing hands. The stock had previously closed at $22.39.
Several analysts have weighed in on CTMX shares. Cantor Fitzgerald started coverage on CytomX Therapeutics in a research report on Monday, October 23rd. They set an “overweight” rating and a $35.00 price objective on the stock. Bank of America lifted their price objective on CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, October 4th. ValuEngine cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Finally, Nomura lifted their price objective on CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a research report on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $32.78.
The company has a market cap of $859.97, a price-to-earnings ratio of -14.38 and a beta of 0.47.
Several hedge funds have recently added to or reduced their stakes in CTMX. New York State Common Retirement Fund raised its holdings in CytomX Therapeutics by 48.8% in the 2nd quarter. New York State Common Retirement Fund now owns 31,100 shares of the biotechnology company’s stock worth $482,000 after acquiring an additional 10,199 shares during the last quarter. Trexquant Investment LP purchased a new position in CytomX Therapeutics in the 3rd quarter worth approximately $474,000. California State Teachers Retirement System raised its holdings in CytomX Therapeutics by 27.8% in the 2nd quarter. California State Teachers Retirement System now owns 51,430 shares of the biotechnology company’s stock worth $797,000 after acquiring an additional 11,200 shares during the last quarter. TIAA CREF Investment Management LLC raised its holdings in CytomX Therapeutics by 183.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 169,552 shares of the biotechnology company’s stock worth $2,628,000 after acquiring an additional 109,791 shares during the last quarter. Finally, American Century Companies Inc. purchased a new position in CytomX Therapeutics in the 2nd quarter worth approximately $922,000. Hedge funds and other institutional investors own 63.13% of the company’s stock.
TRADEMARK VIOLATION WARNING: “CytomX Therapeutics (CTMX) Sets New 12-Month High at $24.95” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3127242/cytomx-therapeutics-ctmx-sets-new-12-month-high-at-24-95.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.